Rules-Based Medicine offers 11 blood-based biomarkers to accelerate your development of new therapies for idiopathic pulmonary fibrosis (IPF).
These biomarkers were chosen in collaboration with the Prognostic Lung Fibrosis Consortium (PROLIFIC) using published data on potential prognostic markers.
RBM offers optimized and highly validated Luminex-based sandwich immunoassays of these biomarkers to support your IPF trials.
These markers have utility in characterizing:
- Epithelial damage (CA 125, CYFRA 21-1, SP-D, CA-19-9, KL-6);
- Fibrosis (MMP-7, Tenascin C);
- Inflammation (CCL18, CXCL13, slCAM1)
- Thrombosis (PAI-1).
*for research use only